Laurus Labs Sees Fair Value Uplift: A Subtle Nod to Execution Confidence
Analysts have nudged the fair value estimate for pharmaceutical player Laurus Labs higher by approximately 6%, a move interpreted less as a major revision and more as a reaffirmation of faith in the company's existing growth trajectory.